Search
News
Trulieve Q2 2026 earnings: Harvest charge drives a $406 million GAAP loss
Trulieve’s Q2 2026 revenue fell 10% to $271.0 million, while diluted EPS from continuing operations declined to a $2.10 loss from a $0.07 loss. A $403.3 million Harvest deconsolidation charge drove a $406.0 million GAAP net loss attributable to common shareholders, but adjusted net income was $20.4 million and adjusted EBITDA was $98.0 million. Gross margin was 60%, with operating cash flow of $53.1 million and free cash flow of $32.1 million, both below the prior-year quarter. Quarter-end cash was $325.4 million.
TradingKey
Fri, Aug 7
Gray Media Q2 2026 Earnings: Political Advertising Drives Profit Recovery
Gray Media (NYSE: GTN) reported Q2 2026 revenue of $839 million, up 9% year over year, while diluted EPS improved to $0.21 from a $0.71 loss. Net income reached $14 million and adjusted EBITDA rose 27% to $214 million, supported by $83 million of political advertising revenue and 10% growth in net retransmission revenue. Core advertising slipped 1%, transaction costs pushed corporate expense above guidance, and first-half operating cash flow fell to $124 million. Q3 guidance calls for revenue of $935 million to $965 million, with political advertising remaining the central growth driver.TradingKey
Fri, Aug 7
Gravity Q2 2026 earnings: Lower operating expenses lift profit despite weaker revenue
Gravity’s Q2 2026 revenue fell 5.2% year over year to KRW 161.88 billion, while operating profit rose 40.2% to KRW 27.58 billion and parent-attributable net profit climbed 83.8% to KRW 24.34 billion. Mobile-game revenue declined 10.7%, more than offsetting 35.0% growth in online games, but a 33.2% reduction in operating expenses lifted operating margin. Sequentially, revenue was flat and operating profit declined as R&D and salary costs increased, making expense discipline and recent Ragnarok launches the main issues after the quarter.
TradingKey
Fri, Aug 7
Century Casinos Q2 2026 earnings: North America offsets Poland weakness
Century Casinos’ Q2 2026 net operating revenue rose 1% to $152.0 million, while diluted loss per share narrowed to $0.39 from $0.40. Adjusted EBITDAR increased 5% to a second-quarter record of $31.7 million as US West revenue climbed 16% and segment EBITDAR rose 93%. Those gains were partly offset by Poland, where revenue fell 19% and Adjusted EBITDAR dropped 97%. Operating earnings improved 4% to $17.2 million, but $25.9 million of interest expense kept the company in a shareholder-attributable net loss.
TradingKey
Fri, Aug 7
China Yuchai 1H 2026 Earnings: Larger-Engine Mix Expands Margins
China Yuchai International’s 1H 2026 revenue rose 13.9% to RMB 14.7 billion as engine sales increased 10.9% to 277,684 units. Gross margin widened to 17.1% from 14.3%, supported by higher volume, a larger-engine sales mix and lower warranty expense, while profit attributable to CYD shareholders climbed 53.2% to RMB 560.6 million. Basic EPS reached RMB 14.94, up from RMB 9.75. Truck, marine and power-generation engines led growth, while agricultural machinery demand declined. The company also reduced borrowings while continuing to invest in research and development.
TradingKey
Fri, Aug 7
Interface Q2 2026 earnings: Gross margin reaches 45% with a tariff refund boost
Interface’s fiscal Q2 2026 net sales rose 5.4% to $395.7 million, while diluted GAAP EPS increased to $0.88 from $0.55. GAAP gross margin reached 45.0%, up 560 basis points, with $15.6 million of IEEPA tariff refunds contributing 393 basis points to adjusted margin expansion. Adjusted EBITDA grew 35.2% to $87.7 million. Interface also raised its full-year sales range to $1.455 billion-$1.485 billion and its adjusted gross margin outlook to 40.6%, based on first-half performance and a robust backlog.
TradingKey
Fri, Aug 7
ACM Research Q2 2026 earnings: ECP growth drives a 36% revenue increase
ACM Research’s Q2 2026 revenue rose 36.0% year over year to $292.9 million, led by 168% growth in ECP, furnace and other technologies and 153% growth in advanced packaging, services and spares. GAAP diluted EPS increased to $1.23 from $0.44, but a $69.6 million unrealized investment gain amplified reported earnings; adjusted diluted EPS was $0.61. Gross margin declined to 46.0%, while GAAP operating margin improved to 17.0%. ACM also raised the low end of its 2026 revenue guidance to $1.125 billion.
TradingKey
Fri, Aug 7
Claritev Q2 FY2026 Earnings: Revenue Grows as Adjusted EBITDA Margin Narrows
Claritev (NYSE: CTEV) reported Q2 FY2026 revenue of $257.5 million, up 6.6% year over year, while its GAAP loss per share narrowed to $3.49 from $3.81. Adjusted EBITDA increased 1.1% to $155.8 million, but the margin fell to 60.5% from 63.8% as service and administrative costs rose faster than revenue. Operating cash flow improved to $92.7 million, and the company raised its 2026 revenue, adjusted EBITDA, and free cash flow guidance.
TradingKey
Fri, Aug 7
MDU Resources Q2 2026 earnings: Utility gains lift net income 55.5%
MDU Resources’ second-quarter 2026 revenue rose approximately 6.8% to $375.2 million, while diluted EPS increased to $0.10 from $0.07 and net income climbed 55.5% to $21.3 million. Electric utility earnings benefited from Badger Wind Farm, new rates and higher retail volumes, and the natural gas distribution loss narrowed, while pipeline earnings declined. The company reaffirmed 2026 EPS guidance of $0.93 to $1.00 as it advanced the proposed $2.7 billion to $3.2 billion Bakken East Pipeline project.
TradingKey
Fri, Aug 7
Collegium Q2 2026 earnings: ADHD growth offsets pain portfolio pressure
Collegium Pharmaceutical’s Q2 2026 net product revenue rose 6% to $199.9 million, while GAAP diluted EPS swung to a $0.46 loss from earnings of $0.34. Adjusted EBITDA increased 8% to $113.8 million as JORNAY PM revenue climbed 41% and AZSTARYS contributed $12.9 million for a partial quarter, offsetting a 9% decline in the pain portfolio. The company lowered full-year product revenue and adjusted EBITDA guidance because authorized-generic Nucynta pricing was weaker than expected, while raising its AZSTARYS revenue range.
TradingKey
Fri, Aug 7
Resmed Q4 FY2026 earnings: Revenue rises 9% as adjusted gross margin expands
Resmed’s fiscal Q4 2026 revenue rose 9% to $1.464 billion, while GAAP diluted EPS increased 2% to $2.64 and non-GAAP diluted EPS advanced 16% to $2.95. A $41.9 million Astral field safety notification expense pushed GAAP gross margin down 200 basis points to 58.8%, even as non-GAAP gross margin expanded 90 basis points to 62.3% on productivity gains. Sleep and Breathing Health remained the main growth engine, but quarterly free cash flow fell 21% to $404 million.TradingKey
Fri, Aug 7
Verrica Q2 2026 Earnings: YCANTH Growth Was Masked by a Milestone Comparison
Verrica Pharmaceuticals’ Q2 2026 revenue fell 53.9% year over year to $5.9 million, while diluted EPS swung to a $0.62 loss from $0.02 of income. U.S. YCANTH net product revenue increased 12.3% to $5.1 million and dispensed applicator units rose 46.1%, but the prior-year quarter included an $8.0 million collaboration milestone. Higher Phase 3 spending, sales-force investment, and a legal settlement widened the net loss to $13.2 million. Cash was $11.2 million at quarter-end, and a new conditional credit facility could extend the runway into 2028.
TradingKey
Fri, Aug 7
Lexicon Q2 2026 Earnings: Licensing Revenue Roll-Off Drives a Net Loss
Lexicon Pharmaceuticals’ Q2 2026 revenue fell to $0.7 million from $28.9 million as the prior-year quarter included $27.5 million of licensing revenue. Diluted EPS moved to a $0.07 loss from $0.01 of income, and the company posted a $31.8 million net loss as R&D spending increased and debt refinancing produced a $4.3 million extinguishment charge. Cash and investments ended June at $190.6 million, while investors await SONATA-HCM data and a planned ZYNQUISTA NDA resubmission.
TradingKey
Fri, Aug 7
Senseonics Q2 2026 Earnings: Revenue Doubles but Expenses Widen Loss
Senseonics’ Q2 2026 revenue rose approximately 120% to $14.5 million, led by U.S. revenue of $12.6 million, while gross margin expanded to about 59% from 47%. Higher commercial integration and product-development spending drove net loss to $36.7 million, or $0.63 per diluted share. The company raised full-year revenue guidance to $62 million-$66 million and gross margin guidance to 58%-61%. Cash, restricted cash and short-term investments totaled approximately $143 million after more than $100 million of financing activity during the quarter.
TradingKey
Fri, Aug 7
INmune Bio Q2 2026 Earnings: Tax-Credit Benefit Narrows Net Loss
INmune Bio reported no revenue in Q2 2026, unchanged year over year, while basic and diluted loss per share narrowed to $0.05 from $1.05 and net loss fell to $1.3 million from $24.5 million. The comparison benefited from a $0.8 million R&D benefit tied mainly to an additional Australian tax rebate and the absence of the prior-year $16.5 million acquired R&D impairment. Cash was $18.4 million at June 30 as Ebstrocel advanced toward UK filing and XPro received FDA Fast Track designation.
TradingKey
Fri, Aug 7
Denali Q2 2026 Earnings: AVLAYAH Launch Generates $3.6 Million
Denali Therapeutics’ Q2 2026 results marked the first full quarter of AVLAYAH commercialization, generating $3.6 million in net product revenue versus none a year earlier. Net loss widened to $127.6 million from $124.1 million, although diluted loss per share narrowed to $0.68 from $0.72. Denali ended June with about $940 million in cash, cash equivalents and marketable securities; July proceeds from a $195 million Priority Review Voucher sale lifted the pro forma balance above $1.1 billion. The company guided Q3 AVLAYAH revenue to $10 million-$12 million.
TradingKey
Fri, Aug 7
electroCore Q2 2026 Earnings: Revenue Rises 28% as Net Loss Narrows
electroCore (NASDAQ: ECOR) reported Q2 2026 net sales of $9.45 million, up approximately 28% year over year, while GAAP net loss narrowed 17% to $3.06 million and diluted loss per share improved to $0.33 from $0.44. Adjusted EBITDA loss improved 26% to $1.75 million. Growth came mainly from VA sales of Rx gammaCore and Quell, alongside higher Truvaga revenue, although gross margin slipped to 86.5% because of a larger inventory reserve. The company raised full-year 2026 revenue guidance to more than 30% growth.
TradingKey
Fri, Aug 7
SIGA Q2 2026 Earnings: Lower TPOXX Sales Compress Revenue and Margins
SIGA Technologies’ Q2 2026 revenue fell 49% year over year to $41.0 million, while diluted EPS declined to $0.17 from $0.49. Product sales totaled $37.9 million, including about $24 million of IV TPOXX delivered to the U.S. strategic national stockpile and $13 million of oral TPOXX sold to two international customers. Operating margin narrowed to 33.9% from 56.3%, reflecting lower sales and a different product mix as SIGA completed the final procurement order under the 19C contract.
TradingKey
Fri, Aug 7
Trevi Q2 2026 earnings: Clinical expansion raises R&D spending
Trevi Therapeutics’ Q2 2026 results reflected accelerating clinical investment rather than commercial revenue. R&D expense rose about 61% to $15.2 million as the company started the Phase 3 OCEAN-1 and Phase 2b LAKE trials, while the net loss widened to $17.8 million, or $0.11 per share. Cash, cash equivalents and marketable securities totaled $318.9 million after an April equity offering generated approximately $162.3 million in net proceeds. Trevi expects this capital to extend its runway into 2030, excluding Haduvio launch costs and a Phase 3 RCC trial.
TradingKey
Fri, Aug 7
Globus Medical Q2 2026 Earnings: Margin Expansion Lifts Adjusted EPS
Globus Medical’s (NYSE: GMED) Q2 2026 earnings showed net sales of $789.6 million, up 5.9% year over year, and GAAP diluted EPS of $1.10, down 26.2% because the prior-year quarter included a $110.5 million Nevro bargain purchase gain. Non-GAAP diluted EPS rose 55.8% to $1.34, while adjusted EBITDA margin expanded to 35.4%. Musculoskeletal Solutions and international sales led growth, offsetting a decline in Enabling Technologies. The company reaffirmed full-year revenue guidance and raised its non-GAAP EPS range to $4.95-$5.05 for 2026.
TradingKey
Fri, Aug 7
Featured Tools
Top News
The Week Ahead: Fed Minutes, Walmart, Target and Home Depot Earnings to Test US Consumer Resilience
SK Hynix Stock Forecast: Can HBM4 Demand Drive a Breakout Toward $194?
Broadcom Stock Price Forecast: Can It Break $500 Before Earnings Amid Strong Custom AI Chip Demand?
New CEO Ternus Launches iPhone 18 Pro on September 9 — Can Apple Reverse Q3 China Miss Before Jackson Hole?
Oracle Stock Forecast: $630 Billion AI Order Backlog Awaits Revaluation, Can the Stock Continue to Recover?
